CVCapsoVision, Inc.
Is the business good?
How good a business is CV?
CapsoVision, Inc. spent more than it took in: an operating loss of $30M on $14M of revenue, 12 months to Q2 2026.
Operating loss · on $14M of revenue · 12 months to Q2 2026
- Share count, year on year
- +2079%
Share count, year on year · shareholders own a smaller slice than a year ago
- Gross margin
- 51%
Gross margin
Details›
- Gross margin12 months to Q2 2026
- 51%
- Operating margin12 months to Q2 2026
- −217%
- Net margin12 months to Q2 2026
- −215%
- Free cash flow margin
- −201%
- R&D as % of revenue
- 155%
- Revenue, trailing twelve months
- $14M
- Free cash flow, trailing twelve months
- −$28M
- Net income, trailing twelve months
- −$30M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Customers and suppliers
Who buys from CV and who it buys from, as the companies report it.
- Customer one9.0%
Share of revenue · FY2025 10-K
None disclosed.
A company has to disclose every customer behind 10% or more of its revenue. Each share comes from the latest annual report of the company that states it and shows on both companies’ pages; CV’s own figures are from its FY2025 10-K. Smaller customers and suppliers go unreported.
Medical Devices
The closest names by size in the same industry